Who are Amitriptyline plus Fluoxitine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amitriptyline-plus-fluoxitine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Amitriptyline plus Fluoxitine — Competitive Intelligence Brief

Amitriptyline plus Fluoxitine (Amitriptyline plus Fluoxitine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidepressant combination (tricyclic antidepressant + SSRI). Area: Psychiatry/Mental Health.

marketed Antidepressant combination (tricyclic antidepressant + SSRI) Serotonin transporter (SERT), norepinephrine transporter (NET) Psychiatry/Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Amitriptyline plus Fluoxitine (Amitriptyline plus Fluoxitine) — Tufts Medical Center. This combination increases serotonin availability in the brain through dual mechanisms: amitriptyline blocks serotonin and norepinephrine reuptake, while fluoxetine selectively inhibits serotonin reuptake.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amitriptyline plus Fluoxitine TARGET	Amitriptyline plus Fluoxitine	Tufts Medical Center	marketed	Antidepressant combination (tricyclic antidepressant + SSRI)	Serotonin transporter (SERT), norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidepressant combination (tricyclic antidepressant + SSRI) class)

Tufts Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amitriptyline plus Fluoxitine — Competitive Intelligence Brief. https://druglandscape.com/ci/amitriptyline-plus-fluoxitine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab